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and Toulouse and Massy, FranceObjectives The aim of this study was to report the long-term clinical outcomes after percutaneous
coronary intervention (PCI) with drug-eluting stents (DES) versus coronary artery bypass grafting
(CABG) for ostial/midshaft lesions in an unprotected left main coronary artery (ULMCA).
Background Data regarding outcomes in these patients are limited.
Methods Of a total of 2,775 patients enrolled in the DELTAmultinational registry, 856 patients with isolated
ostial/midshaft lesions in an ULMCA treated by PCI with DES (n¼ 482) or CABG (n ¼ 374) were analyzed.
Results At a median follow-up period of 1,293 days, there were no signiﬁcant differences in the
propensity score–adjusted analyses for the composite endpoint of all-cause death, myocardial
infarction (MI), and cerebrovascular accident (hazard ratio [HR]: 1.21, 95% conﬁdence interval [CI]: 0.79
to 1.86; p ¼ 0.372), all-cause death (HR: 1.35, 95% CI: 0.80 to 2.27; p ¼ 0.255), the composite endpoint
of all-cause death and MI (HR: 1.33, 95% CI: 0.83 to 2.12; p ¼ 0.235) and major adverse cardiac and
cerebrovascular events (HR: 1.34, 95% CI: 0.93 to 1.93; p ¼ 0.113). These results were sustained after
propensity-score matching. However, a higher incidence of target vessel revascularization (HR: 1.94,
95% CI: 1.03 to 3.64; p ¼ 0.039) was observed in the PCI compared with the CABG group, with a trend
toward higher target lesion revascularization (HR: 2.00, 95% CI: 0.90 to 4.45; p ¼ 0.090).
Conclusions This study demonstrates that PCI for ostial/midshaft lesions in an ULMCA is associatedwith clinical
outcomes comparable to those observed with CABG at long-term follow-up, despite the use of older ﬁrst-
generationDES. (JAmCollCardiol Intv2014;7:354–61)ª2014bytheAmericanCollegeofCardiologyFoundation
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355The left main coronary artery can be divided into 3 seg-
ments: ostial, midshaft, and distal bifurcation. Previous
studies have reported that percutaneous coronary interven-
tion (PCI) with drug-eluting stents (DES) for ostial/mid-
shaft lesions in an unprotected left main coronary artery
(ULMCA) is associated with better clinical outcomes than
PCI for distal bifurcation lesions (1–3). Possible reasons for
this include the fact that ostial/midshaft lesions are in gen-
eral simpler to treat as they do not involve the bifurcation
and that vessel diameter at this location tends to be larger
compared with that in distal bifurcation ULMCA sites,
thus allowing the use of larger diameter stents. This is re-
ﬂected in the current guidelines in which PCI for ostial/
midshaft ULMCA lesions receives a Class IIa recommen-
dation compared with Class IIb for distal bifurcation
ULMCA lesions. However, coronary artery bypass grafting
(CABG) is still considered the gold standard (Class I) (4)
for this lesion subset, although this has not been thoroughly
examined. In the substudy of the MAIN COMPARE
(Revascularization for Unprotected Left Main Coronary
Artery Stenosis: Comparison of Percutaneous Coronary
Angioplasty Versus Surgical Revascularization) study by Lee
et al. (5) (n ¼ 263), PCI for ostial lesions demonstrated
event rates similar to those with CABG for the composite
endpoint of death, myocardial infarction (MI), stroke, and
target vessel revascularization (TVR). The aim of this study
was to compare the long-term clinical outcomes of PCI with
those of CABG, not only for ostial but also for midshaft
ULMCA lesions in an all-comer, larger, international
population.
Methods
The methods of the DELTA registry were published pre-
viously (6). In brief, the registry includes all-comer patients
with ULMCA disease treated with PCI or CABG between
April 2002 and April 2006 in 14 centers. Of the 2,775
patients, 1,118 (40.3%) had ostial/midshaft lesions. A total
of 262 patients who were treated with PCI were excluded as
stenting involved both the ostium/midshaft and distalFrom the *Department of Cardio-Thoracic and Vascular Diseases, San Raffaele Sci-
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isolated ostial/midshaft lesions (not involving the distal left
main bifurcation) (PCI group) were compared with 374
patients treated with CABG (CABG group). Dual anti-
platelet therapy (i.e., aspirin 100 mg daily and clopidogrel 75
mg daily or ticlopidine 250 mg twice daily) was administered
for at least 12 months in the PCI group. In the South
Korean center, cilostazol was also prescribed. Angiographic
follow-up was scheduled according to local guidelines or if a
noninvasive evaluation or clinical presentation suggested
ischemia. Data analysis was performed with the approval of
the institutional ethics committees of the hospitals and/or
universities involved.
Deﬁnitions. In this study, the following events were
analyzed cumulatively at the latest clinical follow-up avail-
able: cardiac and all-cause death, MI, target lesion revas-
cularization (TLR), and TVR. Major adverse cardiac
cerebrovascular events (MACCE) were deﬁned as the
composite endpoint of all-cause death, MI, cerebrovascular
accidents (CVA), and TVR. The occurrence of stent
thrombosis (ST) was deﬁned on the basis of the Academic
Research Consortium deﬁnitions (7) in the PCI group.
Death was classiﬁed as either cardiac or noncardiac. Cardiac
death was deﬁned as any death of a cardiac cause (e.g., MI,
low-output failure, or fatal arrhythmia), procedure-related
death, and death of unknown cause. TLR was deﬁned as any
repeat intervention of the target lesion or other complication
of the target lesion. The target lesion was deﬁned as the
treated segment 5 mm proximally and 5 mm distally to the
stent. TVR was deﬁned as any repeat intervention of any
segment of the target vessel, deﬁned as the entire major
coronary vessel proximal and distal to the target lesion,
including upstream and downstream branches and the target
lesion itself. CVA were deﬁned as stroke, transient ischemic
attacks, and reversible ischemic neurological deﬁcits adju-
dicated by a neurologist and conﬁrmed by computed to-
mography scanning. In-hospital non–Q-wave MI was
deﬁned as the elevation of the serum creatine kinase (CK)
isoenzyme myocardial band that was 3 times the upper limit
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356normal in the CABG group, in the absence of new patho-
logical Q waves. In this analysis we included as cumulative
MIs all Q-wave MIs that occurred during hospital stay and
follow-up and all spontaneous MIs occurring after hospital
discharge. Q-wave MI was deﬁned as the development of
new pathological Q waves in 2 contiguous leads with or
without CK or CK-myocardial band levels elevated above
normal. Spontaneous MI was deﬁned as the occurrence after
hospital discharge of any value of troponin and/or CK-
myocardial band greater than the upper limit of normal if
associated with clinical and/or electrocardiogram change.
The European System for Cardiac Operative Risk Evalua-
tion (EuroSCORE) was calculated. Diagnostic angiogramsAbbreviations
and Acronyms
CABG = coronary artery
bypass grafting
CI = conﬁdence interval
CK = creatine kinase
CVA = cerebrovascular
accident(s)
DES = drug-eluting stent(s)
EuroSCORE = European
System for Cardiac Operative
Risk Evaluation
HR = hazard ratio
MACCE = major adverse
cardiac and cerebrovascular
event(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
ST = stent thrombosis
TLR = target lesion
revascularization
TVR = target vessel
revascularization
ULMCA = unprotected leftwere scored according to the
SYNTAX (Synergy Between
PCI With Taxus and Cardiac
Surgery) score algorithm at the
site laboratory (8).
Study endpoints. The primary
study endpoint was the occurrence
of the composite of all-cause
death,MI, and CVA at long-term
follow-up. Secondary endpoints
were occurrence of all-cause death
and the composite of all-cause
death and MI, MACCE, TVR,
and TLR at long-term follow-up.
Statistical analysis. Data are
presented as percentages and
mean  SD. In general, differ-
ences in proportions were tested
with chi-square test or Fisher
exact test, and differences in
continuous variables were tested
with a Student t test. Cumulative
event curves were generated with
the Kaplan-Meier method and
compared by the log-rank test.
Because of the nonrandomized
nature of the study, a propensity-score analysis was performed to minimize any selection bias
due to the differences in clinical characteristics between the 2
groups. Brieﬂy, for each patient, a propensity score indi-
cating the likelihood of having PCI was calculated by using a
nonparsimonious multivariable logistic regression. A pro-
pensity score, indicating the predicted probability of
receiving a speciﬁc treatment conditional on the observed
covariates, was then calculated from the logistic equation for
each patient. Variables with p < 0.20 on univariate analysis
were included in the logistic regression model to calculate
the propensity score. These were age, sex, hypertension,
diabetes mellitus, chronic kidney disease, EuroSCORE,
unstable angina, acute MI, multivessel disease, and con-
comitant right coronary artery disease. The C-statistic was
main coronary artery0.77 and the Hosmer-Lemeshow test p value was 0.58,
conﬁrming good discrimination and goodness-of-ﬁt of the
propensity-score model, respectively. The individual pro-
pensity score was incorporated into Cox proportional haz-
ards regression models as a covariate as well as treatment
group as the variable of interest to calculate the adjusted
hazard ratio (HR). In addition, to reduce the effect of
treatment-selection bias and potential confounding in this
observational study, we performed rigorous adjustment for
signiﬁcant differences in the baseline characteristics of pa-
tients with propensity-score matching. Clinical outcomes
in the matched population were analyzed with Cox pro-
portional hazards regression stratiﬁed on matched pairs.
Multivariable Cox proportional hazards regression modeling
was performed to determine the independent predictors
of MACCE with purposeful selection of covariates. Vari-
ables associated on univariate analysis (all with a p value
<0.1) and those judged to be of clinical importance from
previous published reports were eligible for inclusion in
the multivariable model-building process. The goodness-
of-ﬁt of the Cox multivariable model was assessed with
the Grønnesby-Borgan-May test. Results are reported
as HR with associated 95% conﬁdence interval (CI) and
p value. Analyses were carried out using SPSS for
Windows, version 19.0 (IBM SPSS Inc., Chicago,
Illinois).
Results
The study population ﬂowchart is shown in Figure 1. A total
of 856 patients were included: 482 treated with PCI and 374
with CABG. Baseline clinical characteristics are summa-
rized in Table 1 and demonstrate that patients in the PCI
group were more frequently male (73.0% vs. 61.8%, p <
0.001), were younger (64.3  11.3 years vs. 66.8  10.0
years, p ¼ 0.001), had a lower EuroSCORE (4.5  3.4 vs.
5.2  2.6, p ¼ 0.003), and had a lower prevalence of hy-
pertension (63.7% vs. 70.6%, p ¼ 0.034) and diabetes
mellitus (26.3% vs. 36.9%, p ¼ 0.001). There was, however,
a higher prevalence of chronic kidney disease (8.3% vs.
4.5%, p ¼ 0.029) and ST-segment elevated MI in the PCI
group (3.7% vs. 0.2%, p ¼ 0.001). Lesion and procedural
characteristics are illustrated in Table 2. As expected, in the
PCI group, the SYNTAX score was lower (26.1  12.3 vs.
35.5  13.1, p < 0.001) with lower occurrence of multi-
vessel disease (70.1% vs. 90.4%, p < 0.001) and concomitant
right coronary artery disease (34.0% vs. 59.1%, p < 0.001).
In-hospital and follow-up MACCE. The median follow-up
period was 1,293 days (interquartile range: 989 to 1,703
days). In-hospital and follow-up MACCE are illustrated in
Table 3. Deﬁnite ST occurred in 3 patients (0.6%), whereas
probable ST was adjudicated to 3 patients (0.6%). Of note,
angiographic follow-up rates in the PCI and CABG groups
were 56.8% versus 10.2%, respectively (p < 0.001).
Figure 1. Study Population Flowchart
CABG ¼ coronary artery bypass grafting; PCI ¼ percutaneous coronary
intervention.




(n ¼ 374) p Value
Male 352 (73.0) 231 (61.8) <0.001
Age, yrs 64.3  11.3 66.8  10.0 0.001
Family history of CAD 149 (30.9) 96 (25.7) 0.092
Hypertension 307 (63.7) 264 (70.6) 0.034
Dyslipidemia 284 (58.9) 240 (64.2) 0.106
Smokers 231 (47.9) 169 (45.2) 0.426
Diabetes 127 (26.3) 138 (36.9) 0.001
IDDM 25 (5.2) 24 (6.4)
NIDDM 102 (21.2) 114 (30.5)
Chronic kidney disease 40 (8.3) 17 (4.5) 0.029
Clinical presentation
Stable angina/silent ischemia 244 (50.6) 121 (32.4) <0.001
Unstable angina 166 (34.4) 197 (52.7) <0.001
NSTEMI 54 (11.2) 55 (14.7) 0.127
STEMI 18 (3.7) 1 (0.2) 0.001
Previous PCI 130 (27.0) 56 (15.0) <0.001
LVEF, % 53.9  12.3 53.5  12.0 0.565
EuroSCORE 4.5  3.4 5.2  2.6 0.003
Values are n (%) or mean  SD.
CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; EuroSCORE ¼
European System for Cardiac Operative Risk Evaluation; IDDM ¼ insulin-dependent diabetes
mellitus; LVEF ¼ left ventricular ejection fraction; NIDDM ¼ non–insulin-dependent diabetes
mellitus; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention; STEMI ¼ ST-segment elevation myocardial infarction.
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357Study endpoints. No signiﬁcant differences in the com-
posite endpoint of all-cause death, MI, and CVA (unad-
justed HR: 1.05, 95% CI: 0.75 to 1.46; p ¼ 0.793;
propensity score–adjusted HR: 1.21, 95% CI: 0.79 to 1.86;
p ¼ 0.372), all-cause death (unadjusted HR: 1.24, 95% CI:
0.82 to 1.88; p ¼ 0.307; propensity score–adjusted HR:
1.35, 95% CI: 0.80 to 2.27; p ¼ 0.255), the composite
endpoint of death and MI (unadjusted HR: 1.09, 95% CI:
0.76 to 1.57; p ¼ 0.623; adjusted HR: 1.33, 95% CI: 0.83 to
2.12; p ¼ 0.235), and MACCE (unadjusted HR: 1.33, 95%
CI: 0.99 to 1.78; p ¼ 0.059; propensity score–adjusted HR:
1.34, 95% CI: 0.93 to 1.93; p ¼ 0.113) were seen between
the 2 groups. A higher TVR (unadjusted HR: 2.15, 95% CI:
1.21 to 3.80; p ¼ 0.009; propensity score–adjusted HR:
1.94, 95% CI: 1.03 to 3.64; p ¼ 0.039) was observed in the
PCI group with a trend toward higher TLR (unadjusted
HR: 2.03, 95% CI: 0.98 to 4.21; p ¼ 0.057; propensity
score–adjusted HR: 2.00, 95% CI: 0.90 to 4.45; p ¼ 0.090).
Kaplan-Meier survival curves for all-cause death, the
composite endpoint of all-cause death and MI, MACCE,
and the composite endpoint of all-cause death, MI, and
CVA are illustrated in Figure 2.
Multivariable analysis for predictors of primary endpoint. At
Cox regression multivariable analysis, PCI for ostial/mid-
shaft ULMCA lesions did not affect the primary endpoint
(HR: 0.99, 95% CI: 0.64 to 1.52; p ¼ 0.948). Age (HR:
1.03, 95% CI: 1.01 to 1.06; p ¼ 0.014), and EuroSCORE
(HR: 1.09, 95% CI: 1.01 to 1.17; p¼ 0.039) were predictors
of the primary endpoint (Table 4).
Propensity score–matched analysis. After propensity-score
matching was performed, 209 pairs were matched. Baseline
clinical and lesion characteristics of the matched groups
are available in the Online Table. After propensity-scorematching, no signiﬁcant differences in the composite
endpoint of all-cause death, MI, and CVA (HR: 1.25, 95%
CI: 0.78 to 2.01; p ¼ 0.350), all-cause death (HR: 1.31,
95% CI: 0.74 to 2.32; p ¼ 0.348), the composite endpoint
of death and MI (HR: 1.38, 95% CI: 0.82 to 2.31; p ¼
0.220), and MACCE (HR: 1.40, 95% CI: 0.93 to 2.10;
p ¼ 0.104) were noted between the 2 groups. There was,
however, a trend toward higher TVR (HR: 1.97, 95% CI:
0.97 to 4.00; p ¼ 0.060) and TLR (HR: 2.23, 95% CI:
0.93 to 5.37; p ¼ 0.073) in the PCI group. Kaplan-Meier
survival curves for all-cause death, the composite endpoint
of all-cause death and MI, MACCE, and the composite
endpoint of all-cause death, MI, and CVA are illustrated
in Figure 3.Discussion
The main ﬁndings of this large, multicenter, multinational,
all-comer registry are the following:
1. PCI for ostial/midshaft lesions with ﬁrst-generation
DES appears to be associated with clinical outcomes
comparable to those seen with CABG at long-term
follow-up. Event rates for the primary endpoint of all-
cause death, MI, and CVA as well as for MACCE
were found to be similar between the 2 groups.




(n ¼ 374) p Value
Multivessel disease 338 (70.1) 338 (90.4) <0.001
RCA disease 164 (34.0) 221 (59.1) <0.001
SYNTAX score* 26.1  12.3 35.5  13.1 <0.001
IABP 15 (3.1) 15 (4.0) 0.478
IVUS 161 (33.4)
Vessels treated 1.17  0.78 2.29  0.98 <0.001
PCI for LAD or LCx 243 (50.4)





Mean stent diameter, mm 3.51  0.36
Mean stent length, mm 15.9  13.5
Maximal balloon diameter, mm 3.88  0.58
Maximal pressure, atm 16.7  3.6
Mean arterial graft 1.9  1.1
Mean venous graft 1.6  1.2
Values are n (%) or mean  SD. *The availability of SYNTAX score is 63.8%.
DES ¼ drug-eluting stent(s); EES ¼ everolimus-eluting stent(s); IABP ¼ intra-aortic balloon
pump; IVUS ¼ intravascular ultrasound; LAD ¼ left anterior descending artery; LCx ¼ left
circumﬂex artery; PES¼ paclitaxel-eluting stent(s); RCA¼ right coronary artery; SES¼ sirolimus-
eluting stent(s); SYNTAX = Synergy Between PCI With Taxus and Cardiac Surgery; ZES ¼
zotarolimus-eluting stent(s); other abbreviations as in Table 1.
Table 3. Cumulative Incidence of In-Hospital and Follow-Up MACCE
PCI (n ¼ 482) CABG (n ¼ 374)
In-hospital events
All-cause death 12 (2.5) 8 (2.1)
Cardiac death 11 (2.3) 4 (1.1)
Noncardiac death 1 (0.2) 4 (1.1)
MI 18 (3.7) 84 (22.5)
Q-wave MI 4 (0.8) 5 (1.3)
Non–Q-wave MI 14 (2.9) 79 (21.2)
Target lesion revascularization 0 0
Target vessel revascularization 5 (1.0) 2 (0.5)
Cerebrovascular accidents 3 (0.6) 5 (1.3)
MACCE 21 (4.3) 20 (5.3)
Events at follow-up
All-cause death 46 (9.5) 29 (7.7)
Cardiac death 26 (5.4) 15 (4.0)
Noncardiac death 20 (4.1) 14 (3.7)
MI 20 (3.9) 18 (4.8)
Target vessel revascularization 45 (9.3) 14 (3.7)
Cerebrovascular accidents 8 (1.7) 8 (2.1)
MACCE 97 (20.1) 58 (15.5)
Values are n (%).
MACCE ¼ major adverse cardiac and cerebrovascular event(s); MI ¼ myocardial infarction;
other abbreviations as in Table 1.
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3582. A higher TVR was observed in the PCI group with a
trend toward higher TLR compared with the CABG
group. There was, however, a signiﬁcantly higher
angiographic follow-up rate in the PCI group, and we
cannot thus exclude that this practice, popular during
the early experience with DES, may have inﬂuenced
the repeat intervention rate observed in this group.
The main DELTA study, in which ULMCA PCI,
irrespective of lesion location was compared with CABG,
demonstrated higher MACCE rate with PCI largely due
to a higher incidence of TVR. In agreement with other
studies, however, no differences were noted in the primary
endpoint of all-cause death, MI, and CVA (6,9–11). In the
current substudy from the DELTA registry, speciﬁcally
focusing on ostial/midshaft lesions, no signiﬁcant differences
were observed between the 2 strategies, not only in the
aforementioned primary endpoint but also in MACCE.
Despite the fact that other studies have examined the role
of PCI compared with CABG in the treatment of
ULMCA disease, the impact of lesion location has not
been fully evaluated. This is particularly important consid-
ering the prevalence of ostial/midshaft lesions (19% to 51%)
(6,9,11–13). In the only study that has examined this, Lee
et al. (5) reported that PCI for ostial ULMCA lesions was
associated with similar MACCE and TVR rates compared
with CABG. This, however, was a small study (n ¼ 123 inPCI group vs. n ¼ 140 in CABG group) and, as the authors
acknowledge, was likely underpowered to detect clinically
signiﬁcant differences in TVR and composite outcomes.
Furthermore, in this study, only ostial lesions were consid-
ered. In contrast, our study not only was larger (n ¼ 482 in
the PCI group vs. n ¼ 374 in the CABG group) but also
included midshaft lesions, thus reﬂecting more accurately
everyday clinical practice. In addition, the relatively large
population size in our study allowed for the generation of
propensity score–matched groups in sufﬁcient numbers for
meaningful conclusions to be made. Our results demonstrate
that the treatment of ostial/midshaft ULMCA lesions with
PCI is associated with long-term outcomes similar to those
observed with CABG for the same lesion subset. In agree-
ment with this, the SYNTAX trial showed similar MACCE
rates with PCI in left main coronary artery patients with low
(0 to 22) or intermediate (23 to 32) scores, whereas those
with high SYNTAX scores (33) demonstrated higher
MACCE rate compared with CABG at 5-year follow-up
(10). With regard to revascularization, TVR was found to be
more common in the PCI group, although it is unclear from
our study whether the higher TVR rate also corresponded to
a higher TLR rate; the latter did not unequivocally differ
between the 2 groups. The signiﬁcant difference in angio-
graphic follow-up between the 2 groups (56.8% vs. 10.2%)
can explain, at least to some extent, the differences noted
between the 2 groups in repeat revascularization, as this can
trigger the oculostenotic reﬂex in both treated ULMCA
Figure 2. Freedom From Cardiac and Cerebrovascular Events in the PCI Group Versus the CABG Group for Ostial/Midshaft Unprotected
Left Main Coronary Artery in the Overall Population
Freedom from all-cause death (A); from the composite endpoint of all-cause death and myocardial infarction (MI) (B); from major adverse cardiac cerebrovascular
events (MACCE) (C); and from the composite endpoint of all-cause death, MI, and cerebrovascular accident (CVA) (D) in the overall population. Patients at risk at
different times are reported below each graph. Abbreviations as in Figure 1.
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359sites that may not require further intervention and in
downstream vessels. The relatively small balloon size (3.88
mm) and less frequent intravascular ultrasound use (33.4%)
during the learning phase of ULMCA PCI, on the other
hand, may have contributed to TLR, which could have beenTable 4. Predictors of the Primary Endpoint at Cox Multivariable Analysis
HR 95% CI p Value
PCI vs. CABG 0.99 0.64–1.52 0.948
Age 1.03 1.01–1.06 0.014
EuroSCORE 1.09 1.01–1.17 0.039
Female 0.81 0.51–1.30 0.389
Diabetes 1.21 0.77–1.88 0.411
LVEF 0.99 0.97–1.01 0.204
Multivessel disease 1.00 0.55–1.84 0.991
AMI 0.91 0.51–1.62 0.739
AMI ¼ acute myocardial infarction; CI ¼ conﬁdence interval; HR ¼ hazard ratio; other
abbreviations as in Table 1.prevented if the current practice of liberal post-dilation and
intravascular imaging was used, factors known to affect
revascularization (14).
In summary, our study suggests that PCI for ostial/mid-
shaft lesions is an acceptable treatment option that seems to
be equivalent to the gold standard of CABG. Importantly,
these results stem from the use of ﬁrst-generation DES
with currently-used devices associated with improved clinical
outcomes in real-world patients, both in ULMCA and
non-ULMCA PCI compared with their earlier counterparts
(15–18). We envisage that the improved efﬁcacy and safety
of new-generation DES in conjunction with the increasing
use of intravascular ultrasound along with advances in
medical therapy will lead to further improvements in clinical
outcomes after ostial/midshaft ULMCA PCI. The results
of the EXCEL Clinical Trial (Evaluation of XIENCE
PRIME Everolimus Eluting Stent System [EECSS] or
XIENCE V EECSS or XIENCE Xpedition EECSS or
XIENCE PRO EECSS Versus Coronary Artery Bypass
Figure 3. Freedom From Cardiac and Cerebrovascular Events in the PCI Group Versus the CABG Group for Ostial/Midshaft Unprotected Left Main
Coronary Artery in the Propensity Score–Matched Groups
Freedom from all-cause death (A); from the composite endpoint of all-cause death and MI (B); from MACCE (C); and from the composite endpoint of all-cause death,
MI, and CVA. (D) in the propensity score–matched groups. Patients at risk at different times are reported below each graph. Abbreviations as in Figures 1 and 2.
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360Surgery for Effectiveness of Left Main Revascularization;
NCT01205776) will shed more light on the subject.
Study limitations. First, this was an observational retro-
spective study. Therefore, multivariable and propensity-
score adjustment was performed to adjust for differences in
baseline clinical and lesion characteristics between the 2
groups. In addition, propensity-score matching was also
undertaken. Second, the majority of DES used in this study
were ﬁrst-generation DES, and thus our results may not
reﬂect outcomes for ULMCA with the currently-used
newer-generation DES. Third, information on symptomatic
graft occlusion in the CABG group is not available. Fourth,
as we do not have complete data regarding the reasons
for repeat revascularization (clinically vs. angiographically
driven), we cannot exclude that in some cases the oculos-
tenotic reﬂex could have driven the repeat revascularization.
Equally important is the fact that the exact site of revascu-
larization is not known. Finally, the low availability (63.8%)
of SYNTAX score in our cohort did not allow us to use
this in the propensity-score analysis.Conclusions
This study demonstrates that PCI for ostial/midshaft lesions
in an ULMCA is associated with comparable clinical out-
comes compared with CABG, despite the use of older, ﬁrst-
generation DES.
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